Skip to main content

Table 1 Novel ADCs in early clinical research in ALL

From: Recent updates for antibody therapy for acute lymphoblastic leukemia

Antibody Target Payload Phase of trial Setting Identifier
ADCT-602 CD22 PBD-dimer toxin I/II R/R CD22+ NCT03698552
ADCT-402 (loncastuximab tesirine) CD19 PBD-dimer toxin I R/R NCT02669264
SGN-CD19A (denintuzumab mafodotin) CD19 monomethyl auristatin F (MMAF) I R/R Ph NCT01786096
ADCT-301 (camidanlumab tesirine) CD25 PBD-dimer toxin I R/R CD25+ AML/ALL NCT02588092
IMGN632 CD123 IGN I R/R CD123+ NCT03386513
  1. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, B-ALL B-cell acute lymphoblastic leukemia, Ph −  Philadelphia chromosome negative, Ph + Philadelphia chromosome positive, R/R relapsed/refractory, T-ALL T-cell acute lymphoblastic leukemia